P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE

• M. R. Clausen,
• F. Offner,
• D. Belada,
• J. Brody,
• K. M. Linton,
• Y. Karimi,
• R. Cordoba,
• S. Snauwaert,
• A. Abbas,
• L. Wang,
• J. Wu,
• B. Elliott,
• L. Falchi

Affiliations

M. R. Clausen

1 Vejle Hospital, Vejle, Denmark

F. Offner

2 Universitair Ziekenhuis Gent, Ghent, Belgium

D. Belada

3 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czechia

J. Brody

4 Icahn School of Medicine at Mount Sinai, New York, United States of America

K. M. Linton

5 The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom

Y. Karimi

6 University of Michigan Comprehensive Cancer Center, Ann Arbor, United States of America

R. Cordoba

7 Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

S. Snauwaert

8 Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium

A. Abbas

9 Genmab, Princeton

L. Wang

9 Genmab, Princeton

J. Wu

10 AbbVie, North Chicago

B. Elliott

9 Genmab, Princeton

L. Falchi

11 Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, United States of America